Vol. 3 No. 5 (2023)
Reimbursement Recommendations

Mavacamten (Camzyos)

Published May 3, 2023

Key Messages

  • CADTH recommends that Camzyos be reimbursed by public drug plans for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) of New York Heart Association (NYHA) class II to III in adult patients if certain conditions are met.
  • Camzyos should only be covered to treat patients who have a documented left ventricular ejection fraction (LVEF) of 55% or greater at rest, determined by echocardiography, a left ventricular (LV) wall thickness of 15 mm or more (or ≥ 13 mm with a family history of hypertrophic cardiomyopathy [HCM]), and a left ventricular outflow tract (LVOT) peak gradient of 50 mm Hg or greater at rest, after Valsalva maneuver, or postexercise as confirmed by echocardiography. To be eligible, patients must also experience either worsening of symptoms or echocardiographically demonstrated deterioration while taking a beta-blocker (BB) or calcium channel blocker (CCB).
  • Camzyos should only be reimbursed if patients are under the care of a cardiologist and if the cost of Camzyos is reduced.